Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 7.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc., and Regeneron.

15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®


February 9, 2019

InterContinental New York Times Square

300 W 44th St.
New York, NY 10036

Overview

click to View Brochure and Agenda

PER’s 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies® is a 1-day educational conference, revolutionizing the presentation of emerging therapies and evolving standards of care in the management of patients with melanoma and other cutaneous malignancies.

Led by world-renowned experts Jeffrey S. Weber, MD, PhD, and Omid Hamid, MD, this international symposium, now in its 15th year, will provide physicians with the tools they need to personalize care for every patient they treat. Sessions will include presentations on advances in immunotherapy, the latest on targeted therapies, the benefits of regional therapy, how to use predictive and prognostic modeling, how to manage treatment-related adverse events associated with emerging strategies, and more! This year’s symposium will once again feature the dynamic and interactive Medical Crossfire® format, where experts will engage in a rigorous debate to answer your questions, and reach consensus on ongoing paradigm shifts. This fast-paced and interactive forum will once again prove highly practical to physicians who treat patients with skin cancer and provide them with unmatched access to the leading experts. Join us in New York, and together, we’ll meet the challenges currently facing the field!

What you will learn at the International Symposium on Melanoma!
 

  • The latest strategies on checkpoint inhibitor strategies, when to use single-agent or combination regiments
  • Insights into the role of other immunotherapy targets including OX40, GITR, IDO, and more
  • Current and emerging combinations to treat BRAF-mutant melanoma
  • Expert perspectives on the management of regional disease and how to prevent recurrence
  • Evolving strategies to mitigate treatment-related toxicities with targeted and immunotherapies

Benefits of Attending

  • Interact with the Expert Faculty and Colleagues
  • Integrate Recent Data into Your Practice Tomorrow!
  • Learn how immunotherapy combinations will change your practice
  • Update your strategies to mitigate treatment-related toxicities
  • Consult with melanoma and other cutaneous disease experts
  • Expand your network of colleagues and peers

Acknowledgement of Commercial Support

This activity is supported by educational grants from Array BioPharma, Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Prometheus Laboratories Inc., and Regeneron.

Target Audience

This educational activity is directed toward medical oncologists, fellows, surgical oncologists, and radiation oncologists who treat patients with skin and other cutaneous malignancies. Dermatologists, dermatopathologists and pathologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma and other cutaneous malignancies will be invited to participate.

Learning Objectives

At the conclusion of this symposium, you should be better prepared to:

  • Discuss the latest clinical trial evidence on current and emerging treatment strategies across cutaneous malignancies, including regional, immuno-, and targeted therapies
  • Demonstrate the impact of multidisciplinary approaches for the identification and management of treatment-related toxicities in patients with cutaneous malignancies
  • Detail the evolving use of biomarkers and other methods to personalize care across treatment settings for patients with melanoma and other cutaneous malignancies
  • Place recent and emerging trial evidence in the context of changing treatment paradigms in order to optimally sequence therapies in the management of melanoma, basal cell carcinoma, Merkel cell carcinoma, and other cutaneous malignancies


Program Co-Chairs

Jeffrey S. Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY


Omid Hamid, MD
Chief, Translational Research & Immuno-Oncology
Director, Cutaneous Malignancies, The Angeles Clinic and Research Institute
Director of Experimental Therapeutics, Cedars Sinai Medical Care Foundation
Los Angeles, CA





Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By